- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT06783439
Évaluation échographique du nerf sciatique chez les patients atteints du syndrome du piriforme (Sciatica)
Piriformis syndrome (PS) is defined as a neuropathy of entrapment resulting from compression and irritation of the sciatic nerve at the level of the piriformis muscle (PM) at the pelvic outlet, causing sciatica radiating to the leg. The neuropathic component of PS is the compression of the sciatic nerve in or around the PM, while the primary cause of the somatic component is myofascial pain of the PM. PS accounts for 6-8% of all hip and sciatic pain cases. It is more common in middle-aged patients, and the most common etiological cause is trauma. There are various methods for the diagnosis of Piriformis Syndrome. Clinically, tenderness on palpation of the PM is the most common symptom. The FAIR test (passive flexion adduction and internal rotation of the hip), the Freiberg test (forceful internal rotation of the thigh in the supine position), the Pace test (abduction of the leg against resistance while sitting) and the Beatty maneuver (active abduction of the thigh on the affected side in the lateral decubitus position) are maneuvers that help in diagnosis. It is known that there is a delay in proximal nerve conduction (H-reflex) on the pathological side compared to the healthy side in the FAIR maneuver on EMG in PS, and it is not a sufficient test for diagnosis alone. Some studies have reported increased piriformis thickness on the pathological side in MRI. None of these clinical and imaging methods are sufficient for diagnosis alone, and today ultrasonography (US) has become one of the most important imaging methods for musculoskeletal clinicians in the diagnosis of PS. Imaging with US and the diagnostic injection test applied to the piriformis muscle with US guidance are quite important for diagnosis. There are a number of studies in the literature evaluating PM with US. These studies have shown that the piriformis muscle thickness and echogenicity increase on the pathological side. However, there is a lack of studies in the literature focusing on the evaluation of the sciatic nerve with US in patients with PS. Our aim in this study is to compare the thickness of the PM and the sciatic nerve by measuring US on both the pathological and painless sides in patients with unilateral hip pain who were diagnosed with PS clinically, to record the variations present in the sciatic nerve, and to determine whether the myofascial pain or the neuropathic component is dominant in the disease.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
The sciatic nerve is the largest nerve in the body and is formed by the ventral roots of the lumbosacral plexus (L4-S3), passes through the foramen ischiadicum majus under the piriformis muscle (PM) and enters the gluteal region. It is controversial whether anatomical variations in the sciatic nerve and PM predispose to the development of Piriformis syndrome (PS). The sciatic nerve passes under the PM as a single branch in almost 90% of cases. However, there are some variations where it passes above and through the muscle or divides into tibial and peroneal branches, with one branch passing under the piriformis. There are a number of studies in the literature evaluating the PM with US. These studies have shown that the PM thickness and echogenicity increase on the pathological side. In addition, it has been mentioned that the sciatic nerve has a coarse and blurry image in patients complaining of sciatic pain. In one study, cross-sectional area measurement was performed instead of PM thickness measurement. However, this was criticized in later studies, and it was stated that it was difficult to calculate muscle volume exactly with two-dimensional US due to the irregular shape of the PM, which is anatomically pear-shaped, and that thickness measurement would provide more accurate results instead of cross-sectional area. In the first study in the literature focusing on the sciatic nerve in PS and the neuropathic pain it causes, it was found that the sciatic nerve was significantly enlarged (75%) on the symptomatic side and had decreased echogenicity in some patients when compared to healthy volunteers.
Type d'étude
Inscription (Réel)
Contacts et emplacements
Lieux d'étude
-
-
-
Istanbul, Turquie (Türkiye)
- İstanbul Üniversitesi - Cerrahpasa (IUC)
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
Méthode d'échantillonnage
Population étudiée
Patients aged between 18 and 70 years with unilateral hip and/or leg pain, positive FAIR (flexion, adduction, internal rotation) test, and tenderness to palpation in the PM will be included in our study.
La description
Inclusion Criteria:
- Patients aged between 18 and 70 years with unilateral hip and/or leg pain
- Positive FAIR (flexion, adduction, internal rotation) test
- Tenderness to palpation in the Piriformis muscle
Exclusion Criteria:
- Patients with a history of previous surgery involving the lumbar and/or hip region
- A history of malignancy or infection in the pelvic region
- Body mass index (BMI) Greater than 30 kg/m2
- Psychiatric diseases
- Vascular disease
- Uncontrolled diabetes, hypertension or heart failure,
- Disc pathologies that may cause radiculopathy
- History of rheumatic disease.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Modèles d'observation: CASE_ONLY
- Perspectives temporelles: CROSS_SECTIONAL
Cohortes et interventions
Groupe / Cohorte |
Intervention / Traitement |
|---|---|
|
Piriformis Syndrome Patients (n=20)
|
The ultrasound probe will be placed parallel to the body of the piriformis muscle on an imaginary line drawn from the sacrum to the greater trochanter of the femur. This area is also the sensitive area of the patients during the examination with pressure, and when the US probe is in this position, the subcutaneous fat tissue, gluteus maximus muscle, piriformis muscle, and the upper and lower borders of the sciatic nerve will be displayed in order from superficial to deep. First, the maximum thickness of the piriformis muscle body will be measured, then the thickness of the sciatic nerve will be measured, and the same measurements will be applied to the patient's asymptomatic hip, and the measurements will be recorded. |
|
Healthy Controls (n=15)
|
The ultrasound probe will be placed parallel to the body of the piriformis muscle on an imaginary line drawn from the sacrum to the greater trochanter of the femur. This area is also the sensitive area of the patients during the examination with pressure, and when the US probe is in this position, the subcutaneous fat tissue, gluteus maximus muscle, piriformis muscle, and the upper and lower borders of the sciatic nerve will be displayed in order from superficial to deep. First, the maximum thickness of the piriformis muscle body will be measured, then the thickness of the sciatic nerve will be measured, and the same measurements will be applied to the patient's asymptomatic hip, and the measurements will be recorded. |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Tenderness in the piriformis muscle by palpation, 0-10 NRS
Délai: Day 1; single study visit
|
Tenderness in the piriformis muscle will be assessed by palpation using the numerical scale (NRS). The numerical scale is a pain score and is evaluated between 0 and 10. |
Day 1; single study visit
|
|
Sciatic nerve thickness (measurement with US)
Délai: Day 1; single study visit
|
Sciatic nerve thickness will be measured with ultrasound on the symptomatic and asymptomatic sides in the same patient. |
Day 1; single study visit
|
|
Piriformis muscle thickness (measurement with US)
Délai: Day 1; single study visit
|
Piriformis muscle thickness will be measured with ultrasound on the symptomatic and asymptomatic sides in the same patient. |
Day 1; single study visit
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chercheur principal: Selim Sezikli, Istanbul Physical Medicine Rehabilitation Training and Research Hospital
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
- La douleur
- Manifestations neurologiques
- Maladies du système nerveux
- Maladies neuromusculaires
- Maladies du système nerveux périphérique
- Névralgie
- Douleur pelvienne
- Mononeuropathies
- Syndromes de compression nerveuse
- Neuropathie sciatique
- Conditions pathologiques, signes et symptômes
- Signes et symptômes
- Sciatique
- Syndrome du muscle piriforme
- Phénomènes physiques
- Radiation
- Rayonnement, non ionisant
- Ondes ultrasoniques
- Son
- Ondes de choc à haute énergie
Autres numéros d'identification d'étude
- 2024-69
- Istanbul PMR (Autre identifiant: Istanbul PMR Training and Research Hospital)
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .